Profiel
Tingzhi Qian worked as the Director-Global Investments & Strategies at Shanghai Fosun High-Tech Group Finance Co., Ltd.
from 2008 to 2013.
After that, Mr. Qian worked as the Executive Director at Xynomic Pharmaceuticals Holdings, Inc. Mr. Qian completed an undergraduate degree at Fudan University, a graduate degree at École des Hautes Études Commerciales de Paris, and another graduate degree at Polytech Clermont-Ferrand.
Eerdere bekende functies van Tingzhi Qian
| Bedrijven | Functie | Einde |
|---|---|---|
Shanghai Fosun High-Tech Group Finance Co., Ltd.
 Shanghai Fosun High-Tech Group Finance Co., Ltd. Financial ConglomeratesFinance Fosun Group Finance Corp., Ltd. provides financial products and services. Its services include financial consulting, guarantee and payment services for member units, insurance agency, entrusted loans and entrusted investments, bills acceptance and discounting, factoring, interbank lending, and fixed income investments. The company was founded in June 2011 and is headquartered in Shanghai, China. | Corporate Officer/Principal | 01-01-2013 |
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Director/Board Member | - |
Opleiding van Tingzhi Qian
| Fudan University | Undergraduate Degree |
| École des Hautes Études Commerciales de Paris | Graduate Degree |
| Polytech Clermont-Ferrand | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Shanghai Fosun High-Tech Group Finance Co., Ltd.
Shanghai Fosun High-Tech Group Finance Co., Ltd. Financial ConglomeratesFinance Fosun Group Finance Corp., Ltd. provides financial products and services. Its services include financial consulting, guarantee and payment services for member units, insurance agency, entrusted loans and entrusted investments, bills acceptance and discounting, factoring, interbank lending, and fixed income investments. The company was founded in June 2011 and is headquartered in Shanghai, China. | Finance |
Xynomic Pharmaceuticals Holdings, Inc.
 Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
